生物学的製剤と低分子化合物で治療している免疫介在性炎症疾患患者の主要心血管イベントリスク: ネットワークメタ解析
CClin Gastroenterol Hepatol 2023;22:961-970.e12
The results of this study show that anti-IL-12/23, JAK inhibitors, and anti-TNF-α were associated with slightly higher risk of MACE compared with placebo. The risk was no different between biologic treatments, and the magnitude of risk did not differ between IMID type.
This meta-analysis by Mattay, et al. included 40 studies and compared MACE incidence between IMID patients treated with JAKi, anti-TNFs, anti-IL-23, anti-IL-12/23, and placebo.
Keywords:
